Used in research and development for treating inflammatory diseases, particularly those involving type 2 immune responses such as asthma, atopic dermatitis, and chronic rhinosinusitis. It neutralizes IL-25 activity, a cytokine that drives Th2 cell activation and production of downstream inflammatory cytokines like IL-4, IL-5, and IL-13. By blocking IL-25, this antibody helps reduce airway inflammation, mucus production, and tissue remodeling in preclinical models. It has served as a tool to validate IL-25 as a therapeutic target and informed the development of other biologics aimed at the IL-25 pathway. Not developed for commercial clinical use but widely used in mechanistic studies and proof-of-concept experiments.